HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jun Chung Selected Research

Arrestin

8/2020Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers.
10/2019Arrestin Domain Containing 3 Reverses Epithelial to Mesenchymal Transition and Chemo-Resistance of TNBC Cells by Up-Regulating Expression of miR-200b.
12/2018The Role of Arrestin Domain-Containing 3 in Regulating Endocytic Recycling and Extracellular Vesicle Sorting of Integrin β4 in Breast Cancer.
8/2017Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3.
1/2014Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jun Chung Research Topics

Disease

19Neoplasms (Cancer)
02/2022 - 04/2004
12Breast Neoplasms (Breast Cancer)
08/2020 - 07/2002
6Neoplasm Metastasis (Metastasis)
08/2020 - 10/2009
5Carcinoma (Carcinomatosis)
05/2011 - 07/2002
3Triple Negative Breast Neoplasms
08/2020 - 12/2018
1Anaplastic Thyroid Carcinoma
11/2010
1Thyroid Neoplasms (Thyroid Cancer)
11/2010
1Carcinogenesis
04/2005
1Hypoxia (Hypoxemia)
07/2004

Drug/Important Bio-Agent (IBA)

13IntegrinsIBA
12/2018 - 07/2002
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2013 - 07/2002
6Integrin alpha6beta4IBA
10/2009 - 07/2002
5ArrestinIBA
08/2020 - 01/2014
3CurcuminIBA
01/2015 - 10/2008
2Pharmaceutical PreparationsIBA
08/2020 - 01/2016
2Biological ProductsIBA
01/2015 - 02/2011
2Growth Factor ReceptorsIBA
05/2011 - 05/2010
2Eukaryotic Initiation Factor-4EIBA
12/2010 - 07/2002
2Small Interfering RNA (siRNA)IBA
11/2010 - 10/2009
2Neoplasm Antigens (Tumor Antigens)IBA
11/2010 - 01/2009
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2005 - 07/2002
1Fluorouracil (Carac)FDA LinkGeneric
08/2020
1DNA (Deoxyribonucleic Acid)IBA
08/2020
1UracilIBA
08/2020
1MicroRNAs (MicroRNA)IBA
08/2020
1Epidermal Growth Factor (EGF)IBA
12/2018
1Antineoplastic Agents (Antineoplastics)IBA
08/2017
1ArrestinsIBA
08/2017
1selinexorIBA
08/2017
1Phenobarbital (Luminal)FDA Link
08/2017
1Sirolimus (Rapamycin)FDA Link
03/2015
1Insulin-Like PeptidesIBA
03/2015
1Eukaryotic Initiation Factor-4F (EIF4F)IBA
11/2013
1Peptide Initiation Factors (Initiation Factor)IBA
12/2010
1AgarIBA
11/2010
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
05/2010
1Phosphotransferases (Kinase)IBA
05/2010
1tyrosine receptor (receptor, tyrosine)IBA
05/2010
1Integrin beta4IBA
10/2009
1Laminin (Merosin)IBA
10/2008
1adhesion receptorIBA
10/2008
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
04/2005
1Tyrosine Kinase InhibitorsIBA
04/2005
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
07/2004
1Protein Kinase C-alphaIBA
07/2004
1Integrin alpha6beta1IBA
07/2004
1Integrin alpha6IBA
04/2004
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
04/2004
1Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA
07/2002

Therapy/Procedure

2Therapeutics
08/2020 - 04/2004
1Reoperation
02/2022